TRENTAL TABLET (EXTENDED-RELEASE)

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PENTOXIFYLLINE

から入手可能:

SANOFI-AVENTIS CANADA INC

ATCコード:

C04AD03

INN（国際名）:

PENTOXIFYLLINE

投薬量:

400MG

医薬品形態:

TABLET (EXTENDED-RELEASE)

構図:

PENTOXIFYLLINE 400MG

投与経路:

ORAL

パッケージ内のユニット:

60

処方タイプ:

Prescription

治療領域:

HEMORRHEOLOGIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0115837001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2013-03-01

製品の特徴

_ _
_ _
_Page 1 of 21_
PRODUCT MONOGRAPH
P
r
TRENTAL
®
(pentoxifylline sustained release tablets, 400 mg Mfr. Std.)
Vasoactive agent
ATC Code : C04AD03
sanofi-aventis Canada Inc.
DATE OF REVISION:
2150 St. Elzear Blvd. West
MARCH 30, 2011
Laval, Quebec H7L 4A8
SUBMISSION CONTROL NO.: 142355
s-a Version dated
_ _
_ _
_Page 2 of 21_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................. 3
SUMMARY
PRODUCT
INFORMATION........................................................ 3
INDICATIONS
AND
CLINICAL
USE ............................................................. 3
CONTRAINDICATIONS
..................................................................................
3
WARNINGS
AND
PRECAUTIONS
................................................................. 4
ADVERSE
REACTIONS...................................................................................
5
DRUG
INTERACTIONS
...................................................................................
7
DOSAGE
AND
ADMINISTRATION
............................................................... 8
OVERDOSAGE
.................................................................................................
8
ACTION
AND
CLINICAL
PHARMACOLOGY.............................................. 9
STORAGE
AND
STABILITY
...........................................................................
9
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ............................. 10
PART II: SCIENTIFIC INFORMATION
....................................................... 11
PHARMACEUTICAL
INFORMATION.........................................................
11
DETAILED
PHARMACOLOGY
....................................................................
12
TOXICOLOGY
................................................................................................
14
REFERENCES
.................................................................................................
18
PART III: CONSUMER
INFORMATION...................................................... 20